161 related articles for article (PubMed ID: 32770197)
21. NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25-case cohort study.
Chen W; Hornick JL; Fletcher CDM
Histopathology; 2021 Jan; 78(2):334-337. PubMed ID: 32779239
[TBL] [Abstract][Full Text] [Related]
22. Primary intradural extramedullary spinal mesenchymal chondrosarcoma: case report and literature review.
Chen CW; Chen IH; Hu MH; Lee JC; Huang HY; Hong RL; Yang SH
BMC Musculoskelet Disord; 2019 Sep; 20(1):408. PubMed ID: 31484514
[TBL] [Abstract][Full Text] [Related]
23. NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.
Yoshida KI; Machado I; Motoi T; Parafioriti A; Lacambra M; Ichikawa H; Kawai A; Antonescu CR; Yoshida A
Am J Surg Pathol; 2020 Jun; 44(6):719-728. PubMed ID: 31972596
[TBL] [Abstract][Full Text] [Related]
24. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
[TBL] [Abstract][Full Text] [Related]
25. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
26. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
de Andrea CE; San-Julian M; Bovée JVMG
Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
[TBL] [Abstract][Full Text] [Related]
27. A mesenchymal chondrosarcoma with aberrant nuclear expression of STAT6: a potential diagnostic pitfall.
Broggi G; Mazzucchelli M; Covello R; Casini B; Barbagallo GMV; Salvatorelli L; Magro G
Pathol Res Pract; 2022 Apr; 232():153803. PubMed ID: 35217266
[TBL] [Abstract][Full Text] [Related]
28. FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.
Lee AF; Hayes MM; Lebrun D; Espinosa I; Nielsen GP; Rosenberg AE; Lee CH
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):233-8. PubMed ID: 21084965
[TBL] [Abstract][Full Text] [Related]
29. Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.
Safaric Tepes P; Segovia D; Jevtic S; Ramirez D; Lyons SK; Sordella R
Lab Invest; 2022 Sep; 102(9):1038-1049. PubMed ID: 34837064
[TBL] [Abstract][Full Text] [Related]
30. Intraparenchymal mesenchymal chondrosarcoma of the frontal lobe--a case report and molecular detection of specific gene fusions from archival FFPE sample.
Sajjad EA; Sikora K; Paciejewski T; Garbicz F; Paskal W; Szacht M; Grajkowska W; Włodarski PK
Clin Neuropathol; 2015; 34(5):288-93. PubMed ID: 25907264
[TBL] [Abstract][Full Text] [Related]
31. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton.
Müller S; Söder S; Oliveira AM; Inwards CY; Aigner T
Mod Pathol; 2005 Aug; 18(8):1088-94. PubMed ID: 15731776
[TBL] [Abstract][Full Text] [Related]
32. [Expression and diagnostic value of NKX3.1 and NKX2.2 in mesenchymal chondrosarcoma].
Wang XX; Chen H; Wang X; Ma L; Cheng K; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Feb; 51(2):114-119. PubMed ID: 35152629
[No Abstract] [Full Text] [Related]
33. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.
El Beaino M; Roszik J; Livingston JA; Wang WL; Lazar AJ; Amini B; Subbiah V; Lewis V; Conley AP
Curr Oncol Rep; 2018 Mar; 20(5):37. PubMed ID: 29582189
[TBL] [Abstract][Full Text] [Related]
34. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
35. NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
Yoshida A; Sekine S; Tsuta K; Fukayama M; Furuta K; Tsuda H
Am J Surg Pathol; 2012 Jul; 36(7):993-9. PubMed ID: 22446943
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases.
Shakked RJ; Geller DS; Gorlick R; Dorfman HD
Arch Pathol Lab Med; 2012 Jan; 136(1):61-75. PubMed ID: 22208489
[TBL] [Abstract][Full Text] [Related]
37. Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Santi M; Judkins AR; Rushing EJ
Ann Diagn Pathol; 2010 Feb; 14(1):8-14. PubMed ID: 20123451
[TBL] [Abstract][Full Text] [Related]
38. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
39. Pediatric Soft Tissue Tumors With BCOR ITD Express EGFR but Not OLIG2.
Salgado CM; Zin A; Garrido M; Kletskaya I; DeVito R; Reyes-Múgica M; Bisogno G; Donofrio V; Alaggio R
Pediatr Dev Pathol; 2020; 23(6):424-430. PubMed ID: 32790583
[TBL] [Abstract][Full Text] [Related]
40. Primary paediatric epidural sarcomas: molecular exploration of three cases.
Low SYY; Kuick CH; Seow WY; Bte Syed Sulaiman N; Chen H; Lian DWQ; Chang KTE; Tan EEK; Soh SY; Tan GIL; Ng LP; Seow WT; Low DCY
BMC Cancer; 2019 Feb; 19(1):182. PubMed ID: 30819134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
